Xponance’s Intellia Therapeutics NTLA Stock Holding History

Xponance’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$225K	Buy	+13,318	New	+$186K	﹤0.01%	1553
2023 Q3	–	Sell	-5,163	Closed	-$211K	–	1262
2023 Q2	$211K	Buy	+5,163	New	+$209K	﹤0.01%	1136
2022 Q4	–	Sell	-4,250	Closed	-$238K	–	1240
2022 Q3	$238K	Buy	4,250 +210	+5%	+$13K	﹤0.01%	1057
2022 Q2	$209K	Buy	4,040 +732	+22%	+$37.2K	﹤0.01%	1085
2022 Q1	$240K	Buy	3,308 +14	+0.4%	+$1.19K	﹤0.01%	1068
2021 Q4	$389K	Buy	3,294 +47	+1%	+$5.89K	0.01%	990
2021 Q3	$436K	Sell	3,247 -251	-7%	-$38K	0.01%	942
2021 Q2	$566K	Buy	+3,498	New	+$272K	0.01%	868

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Xponance's NTLA Position: Q2 2026 in Review

Xponance opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 13,318 shares worth $225K. The stake represents ﹤0.01% of the portfolio and ranks #1553 among its holdings. This is a return to the name: Xponance previously reported a position in NTLA as recently as Q2 2023.

Xponance first reported a position in NTLA in Q2 2021 and has held it in 8 quarters since. The position peaked at $566K in Q2 2021. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Xponance held 13,318 shares of Intellia Therapeutics worth $225K as of Q2 2026.
Intellia Therapeutics was a new Xponance position in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1553 holding.
Xponance first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 8 quarters since.
Xponance's Intellia Therapeutics position peaked at $566K in Q2 2021.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.